← Back to patent-cliff list
Weersuntinib
Tier C — Watch / tradeWeersuntinib
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDI
Indications (approved)：食管鳞状细胞癌, Solid tumour, Cachexia, Oesophageal cancer
Regional status
US
Phase I
2022-02-21
EU
-
China
Phase II
2024-08-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Weersuntinib?
Approved indications include: 食管鳞状细胞癌, Solid tumour, Cachexia, Oesophageal cancer.
When does the Weersuntinib patent expire?
No public expiry year is available for Weersuntinib yet; this page updates once verified.
How do I get a quote for Weersuntinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01